Retatrutide may be available as a research peptide, but that is not the same as an approved personal treatment
Retatrutide is an investigational peptide that belongs to a class of medications known as incretin mimetics
and its subsidiary Hims, Inc
Conversely, Novo Nordisk faces a more daunting challenge: as Retatrutide's marketing authorization advances and the 2027 patent cliff approaches, existing revenue from Semaglutide will be eroded on two fronts, raising the question of how Novo Nordisk will fill the resulting gap
It is also commonly studied for its potential effects on sleep quality, appetite regulation, and lean mass development.
Its a simple question, but the answer can vary depending on your specific peptide, desired dosage, and personal protocol